Contactez-nous
À propos de la société
Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.
US
Inconnue
Entreprise non vérifiée
Transparence commerciale
- Informations sur l'entreprise non vérifiées
- Demandez à leurs clients des avis
- N'a pas répondu aux avis négatifs